King's College London Repurposes KCL-286 for Alzheimer's Treatment

Scientists at King's College London just found that an experimental drug built for spinal cord injuries might fight Alzheimer's disease instead. The compound is called KCL-286. It works by repairing broken DNA and calming brain inflammation in mice. Most Alzheimer's treatments focus only on toxic protein buildup. This pill takes a totally different route by tackling cell damage early on. The best part is that it already cleared Phase one human safety trials. That means the usual multi-year timeline for drug testing could shrink fast. Professor Jonathan Corcoran noted it is an orally bioavailable small molecule. Patients take it by mouth instead of getting painful injections. Dr. Maria Goncalves stressed that it targets processes happening at the very start of the disease. Researchers still need to prove it actually works against Alzheimer's in humans.